Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19040329 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | January 2025 | May 2025 | Allow | 3 | 0 | 1 | Yes | No |
| 18820232 | USE OF REBOXETINE TO TREAT NARCOLEPSY | August 2024 | March 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 18809731 | DEVICE AND METHOD FOR PRODUCING HIGH-PRESSURE OR SUPER HIGH-PRESSURE STEAM AS BYPRODUCT FROM MALEIC ANHYDRIDE PRODUCING DEVICE | August 2024 | April 2025 | Allow | 8 | 1 | 1 | Yes | No |
| 18787536 | Systems and methods for the production of levulinic acid, furfural, and formic acid | July 2024 | October 2024 | Allow | 2 | 0 | 0 | Yes | No |
| 18765167 | SYNTHETIC PROGESTOGENS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | July 2024 | December 2024 | Allow | 5 | 1 | 0 | No | No |
| 18670653 | LOW-TEMPERATURE CONTINUOUS-FLOW PREPARATION METHOD OF BEDAQUILINE | May 2024 | July 2024 | Allow | 2 | 0 | 0 | No | No |
| 18654002 | BIMETALLIC METAL-ORGANIC FRAMEWORKS NANOSHEET BASED ON ZEOLITE IMIDAZOLE FRAMEWORK/MATERIALS OF INSTITUTE LAVOISIER TOPOLOGY AND PREPARATION METHOD AND APPLICATION THEREOF | May 2024 | October 2024 | Allow | 5 | 0 | 1 | No | No |
| 18573904 | NOVEL BIFUNCTIONAL HETEROCYCLIC COMPOUND HAVING BTK DEGRADATION FUNCTION VIA UBIQUITIN PROTEASOME PATHWAY, AND USE THEREOF | December 2023 | June 2024 | Allow | 6 | 0 | 0 | Yes | No |
| 18529515 | 6-(4-HYDROXYPHENYL)-2-(2-ETHOXYETHOXY)-4-(4-METHOXYPHENYL)NICOTINONITRILE AS AN ANTIMICROBIAL COMPOUND | December 2023 | July 2024 | Allow | 7 | 2 | 1 | Yes | No |
| 18521663 | SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | November 2023 | April 2025 | Allow | 17 | 0 | 1 | No | No |
| 18508164 | 1,4-DIVINYLPHENYLENE-BRIDGED DIRUTHENIUM COMPLEX BEARING TWO Ru(CO)(PiPR3)2 MOIETIES WITH 8-MERCAPTOQUINOLATO CO-LIGAND AS AN ORGANIC CATALYST | November 2023 | December 2024 | Allow | 13 | 2 | 1 | No | No |
| 18385578 | 8-((3,4-DIHYDROXYPHENYL)DIAZENYL)NAPHTHALENE-1,3-DISULFONIC ACID AS AN ANTIOXIDANT COMPOUND | October 2023 | February 2025 | Allow | 15 | 3 | 0 | No | Yes |
| 18385561 | 8-((4-HYDROXY-3-METHYLPHENYL)DIAZENYL)NAPHTHALENE-1,3-DISULFONIC ACID AS AN ANTIMICROBIAL COMPOUND | October 2023 | June 2025 | Abandon | 19 | 4 | 0 | No | No |
| 18384771 | 8-((3-FORMYL-4-HYDROXYPHENYL)DIAZENYL)NAPHTHALENE-1,3-DISULFONIC ACID AS AN ANTIOXIDANT COMPOUND | October 2023 | February 2025 | Allow | 16 | 3 | 0 | Yes | Yes |
| 18384785 | 8-[(2-HYDROXYNAPHTHALEN-1-YL)DIAZENYL]NAPHTHALENE-1,3-DISULFONIC ACID AS AN ANTIOXIDANT COMPOUND | October 2023 | May 2025 | Abandon | 18 | 3 | 0 | No | No |
| 18384197 | FUSED BICYCLIC ALKYLENE LINKED IMIDODICARBONIMIDIC DIAMIDES, METHODS FOR SYNTHESIS, AND USES IN THERAPY | October 2023 | March 2025 | Allow | 17 | 1 | 1 | Yes | No |
| 18492746 | PROTEOLYSIS-TARGETING CHIMERIC MOLECULES (PROTACS) THAT INDUCE DEGRADATION OF INDOLEAMINE 2,3-DIOXYGENASE (IDO) PROTEIN | October 2023 | January 2025 | Allow | 15 | 0 | 0 | Yes | No |
| 18379559 | N-(NAPHTHALEN-1-YLCARBAMOTHIOYL)FURAN-2-CARBOXAMIDE AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.) | October 2023 | December 2023 | Allow | 2 | 0 | 0 | Yes | No |
| 18475724 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | September 2023 | February 2025 | Allow | 16 | 1 | 1 | No | No |
| 18233090 | CONTRACEPTIVE COMPOUNDS AND METHODS | August 2023 | December 2024 | Allow | 16 | 0 | 0 | Yes | No |
| 18365877 | SYNTHETIC PROGESTOGENS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | August 2023 | February 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18229353 | PLK1 SELECTIVE DEGRADATION INDUCING COMPOUND | August 2023 | July 2025 | Abandon | 23 | 0 | 1 | No | No |
| 18220856 | CANNABIS BASED THERAPEUTIC AND METHOD OF USE | July 2023 | July 2025 | Allow | 24 | 1 | 0 | No | No |
| 18347808 | ULTRA SHORT ACTING ANTI-ARRHYTHMIC AGENTS | July 2023 | November 2024 | Allow | 16 | 0 | 0 | Yes | No |
| 18339227 | MACROCYCLIC COMPOUND AND USES THEREOF | June 2023 | May 2025 | Allow | 23 | 1 | 1 | No | No |
| 18209699 | BROMOCRIPTINE FORMULATIONS | June 2023 | December 2024 | Allow | 18 | 0 | 0 | Yes | No |
| 18206953 | PROCESS OF MAKING DERIVATIVES OF SUBSTITUTED MORPHOLINES | June 2023 | December 2023 | Allow | 6 | 1 | 0 | Yes | No |
| 18204566 | ALPHA POLYGLUTAMATED PEMETREXED AND USES THEREOF | June 2023 | June 2025 | Allow | 24 | 1 | 0 | Yes | No |
| 18318939 | AROMATIC BORON-CONTAINING COMPOUNDS AND RELATED INSULIN ANALOGS | May 2023 | December 2023 | Allow | 60 | 0 | 1 | Yes | No |
| 18318158 | METHODS, COMPOSITIONS, AND KITS ADDRESSING DEPRESSED MOOD | May 2023 | June 2025 | Abandon | 25 | 0 | 1 | No | No |
| 18141999 | DEUTERATED ANALOGS OF ETIFOXINE, THEIR DERIVATIVES AND USES THEREOF | May 2023 | June 2025 | Allow | 25 | 1 | 0 | Yes | No |
| 18307174 | SUBSTITUTED ALKYLPHENOLS AS HCN1 ANTAGONISTS | April 2023 | November 2024 | Allow | 19 | 0 | 0 | Yes | No |
| 18305611 | FREE BASE CRYSTALLINE FORM OF A COMPLEMENT COMPONENT C5a RECEPTOR | April 2023 | June 2025 | Abandon | 26 | 1 | 0 | No | No |
| 18137766 | CANNABINOID CONJUGATE MOLECULES | April 2023 | November 2023 | Allow | 7 | 0 | 1 | Yes | No |
| 18304764 | ORGANIC ELECTRO-OPTIC CHROMOPHORES | April 2023 | March 2025 | Allow | 23 | 0 | 1 | Yes | No |
| 18303267 | USE OF TRANS-[TETRACHLOROBIS(1H-INDAZOLE)RUTHENATE(III)] FOR THE TREATMENT OF CANCER | April 2023 | June 2025 | Abandon | 26 | 1 | 0 | Yes | No |
| 18135225 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | April 2023 | June 2025 | Abandon | 26 | 1 | 0 | Yes | No |
| 18297973 | ORAL CANNABINOID PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING SLEEP DISORDERS | April 2023 | July 2023 | Allow | 3 | 0 | 0 | No | No |
| 18131052 | CANNABIS BASED THERAPEUTIC AND METHOD OF USE | April 2023 | March 2025 | Allow | 24 | 1 | 0 | Yes | No |
| 18130178 | CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) INHIBITOR AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAID INHIBITOR FOR USE IN THE TREATMENT OR PREVENTION OF CARDIOVASCULAR DISEASES | April 2023 | September 2024 | Allow | 17 | 0 | 1 | Yes | No |
| 18185555 | SOLID FORMS COMPRISING AN OXIME ETHER COMPOUND, COMPOSITIONS AND METHODS OF USE THEREOF | March 2023 | May 2025 | Abandon | 26 | 0 | 1 | No | No |
| 18121694 | HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | March 2023 | October 2024 | Allow | 19 | 1 | 0 | Yes | No |
| 18119564 | PROLONGED ECTOPARASITE-CONTROLLING AGENT FOR ANIMAL | March 2023 | March 2025 | Allow | 25 | 2 | 0 | Yes | No |
| 18119751 | COUMARIN COMPOUNDS AS ANTIBACTERIAL AGENTS | March 2023 | December 2023 | Allow | 9 | 2 | 0 | Yes | No |
| 18117257 | Compositions and Methods of Modulating Short-Chain Dehydrogenase Activity | March 2023 | June 2025 | Abandon | 27 | 1 | 1 | Yes | No |
| 18115966 | TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH | March 2023 | May 2024 | Allow | 14 | 0 | 0 | Yes | No |
| 18114055 | BORATE SALTS, POLYMERS AND COMPOSITES | February 2023 | July 2024 | Allow | 16 | 0 | 1 | No | No |
| 18169716 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | February 2023 | September 2024 | Allow | 19 | 1 | 0 | No | No |
| 18157593 | CO-CRYSTALS OF BOSCALID AND TRIAZOLES | January 2023 | July 2024 | Allow | 18 | 0 | 1 | Yes | No |
| 18096272 | COMPOUNDS WITH HIV MATURATION INHIBITORY ACTIVITY | January 2023 | April 2025 | Abandon | 27 | 1 | 1 | No | No |
| 18152098 | DENDRILLA MEMBRANOSA COMPOUNDS, DERIVATIVES THEREOF, AND USES THEREOF | January 2023 | February 2025 | Allow | 25 | 2 | 1 | No | No |
| 18069943 | METHOD FOR MANUFACTURING METHYLTETRAHYDROPHTHALIC ANHYDRIDE | December 2022 | August 2024 | Allow | 60 | 3 | 0 | Yes | No |
| 18084307 | AMINO ACID COMPOUNDS AND METHODS OF USE | December 2022 | May 2024 | Allow | 17 | 0 | 0 | Yes | No |
| 18067456 | READY-TO-USE BARRIER AND KNOCKDOWN PESTICIDES | December 2022 | January 2024 | Allow | 13 | 2 | 1 | Yes | No |
| 18082973 | Methods of Treating Residual Lesions of Vascular Anomalies | December 2022 | May 2025 | Abandon | 29 | 2 | 0 | Yes | No |
| 18062683 | Fospropofol Salts, Methods And Compositions | December 2022 | March 2025 | Allow | 27 | 2 | 0 | Yes | No |
| 18075664 | CHEMICAL COMPOUNDS | December 2022 | December 2024 | Abandon | 24 | 0 | 1 | No | No |
| 17990427 | CD16A BINDING AGENTS AND USES THEREOF | November 2022 | July 2024 | Allow | 19 | 0 | 1 | Yes | No |
| 17925923 | ANTI-CANCER SPIROCYCLIC-GUANIDINE COMPOUNDS AND USES THEREOF | November 2022 | June 2025 | Allow | 31 | 0 | 0 | Yes | No |
| 17982859 | CANNABINOID CONJUGATE MOLECULES | November 2022 | March 2023 | Allow | 4 | 0 | 1 | Yes | No |
| 17982779 | CANNABINOID CONJUGATE MOLECULES | November 2022 | March 2023 | Allow | 5 | 0 | 1 | Yes | No |
| 17982233 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | November 2022 | February 2025 | Allow | 27 | 1 | 1 | Yes | No |
| 17974804 | COMPOSITIONS COMPRISING IBRUTINIB AND AN ALKALOID HAVING ENHANCED BIOAVAILABILITY | October 2022 | May 2025 | Abandon | 30 | 2 | 1 | No | No |
| 18048016 | COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS | October 2022 | December 2024 | Allow | 26 | 1 | 0 | Yes | No |
| 17967767 | SYNTHETIC PROGESTOGENS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | October 2022 | May 2024 | Allow | 19 | 1 | 0 | No | No |
| 17964491 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | October 2022 | October 2024 | Allow | 24 | 2 | 1 | Yes | No |
| 17954740 | Methods for Producing Nitroso Compound and Quinoxaline Compound | September 2022 | May 2024 | Allow | 19 | 0 | 0 | Yes | No |
| 17955182 | THERAPEUTIC CONJUGATES | September 2022 | April 2024 | Allow | 19 | 0 | 1 | Yes | No |
| 17934964 | POST POLYMERIZATION MODIFICATION IN FLOW | September 2022 | October 2024 | Allow | 25 | 2 | 0 | Yes | No |
| 17948162 | AMINOALKANOIC ACID DERIVATIVE CONTAINING BIPHENYL GROUP AND USE OF THE SAME | September 2022 | October 2024 | Allow | 25 | 0 | 1 | Yes | No |
| 17948157 | PHARMACEUTICAL COMPOSITION COMPRISING AMINOALKANOIC ACID DERIVATIVE CONTAINING BIPHENYL GROUP | September 2022 | April 2024 | Allow | 19 | 0 | 1 | Yes | No |
| 17948165 | METHOD FOR PREPARING AMINOALKANOIC ACID DERIVATIVE CONTAINING BIPHENYL GROUP | September 2022 | June 2024 | Allow | 21 | 2 | 0 | Yes | No |
| 17946898 | Small Molecule Binders of the Oncogenic Fusion Transcription Factor PAX3-FOXO1 | September 2022 | December 2023 | Allow | 23 | 0 | 1 | Yes | No |
| 17893292 | SYNTHESIS ROUTES TO ACCESS MDMA PRODRUGS BY USING CONTROLLED AND NON-CONTROLLED INTERMEDIATES | August 2022 | November 2023 | Allow | 15 | 1 | 0 | Yes | No |
| 17819695 | PROCESS FOR PRODUCING SUBSTITUTED AMINO ALCOHOLS | August 2022 | April 2025 | Abandon | 32 | 2 | 0 | Yes | No |
| 17887854 | MEDICAMENT COMPRISING COMBINATION OF SEPETAPROST AND RHO-ASSOCIATED COILED-COIL CONTAINING PROTEIN KINASE INHIBITOR | August 2022 | September 2024 | Allow | 25 | 1 | 1 | Yes | No |
| 17886807 | TRICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | August 2022 | March 2024 | Allow | 19 | 1 | 0 | No | No |
| 17818378 | COMPOSITION FOR PREVENTING OR TREATING KELOID | August 2022 | May 2024 | Allow | 21 | 2 | 1 | No | No |
| 17880720 | MODULATOR OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR | August 2022 | February 2025 | Allow | 30 | 2 | 0 | Yes | Yes |
| 17880101 | METHOD OF TREATING STIMULANT USE DISORDER USING A COMBINATION OF TOPIRAMATE AND PHENTERMINE | August 2022 | October 2024 | Allow | 26 | 2 | 0 | Yes | No |
| 17871065 | FORMULATIONS OF T-TYPE CALCIUM CHANNEL MODULATORS AND METHODS OF USE THEREOF | July 2022 | March 2024 | Allow | 20 | 1 | 0 | No | No |
| 17867216 | DINITROXIDE BIRADICAL COMPOUNDS AS POLARIZING AGENTS | July 2022 | January 2025 | Abandon | 30 | 2 | 1 | Yes | No |
| 17864307 | 3-SUBSTITUTED PIPERIDINE COMPOUNDS FOR CBL-B INHIBITION, AND USE THEREOF | July 2022 | November 2023 | Allow | 16 | 0 | 0 | Yes | No |
| 17856502 | PHARMACEUTICAL COMPOSITIONS AND METHODS UTILIZING NEOSTIGMINE AND AN NK-1 ANTAGONIST FOR TREATING MYASTHENIA GRAVIS | July 2022 | March 2024 | Allow | 20 | 0 | 0 | Yes | No |
| 17856605 | SYNTHETIC PROGESTOGENS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | July 2022 | September 2022 | Allow | 2 | 0 | 0 | Yes | No |
| 17852525 | COSMETIC COMPOSITION CONTAINING A RHEOLOGICAL-MODIFYING AND STABILIZING POLYMER BLEND | June 2022 | October 2024 | Allow | 27 | 2 | 1 | Yes | Yes |
| 17853623 | SYNTHETIC PROGESTOGENS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | June 2022 | August 2022 | Allow | 2 | 0 | 0 | Yes | No |
| 17852774 | METHOD FOR TREATMENT OF PANCREATITIS | June 2022 | June 2025 | Allow | 36 | 1 | 0 | Yes | No |
| 17852475 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING RADIATION-INDUCED BYSTANDER EFFECTS CAUSED BY RADIATION OR RADIOTHERAPY | June 2022 | February 2025 | Allow | 32 | 2 | 1 | Yes | No |
| 17845767 | USE OF REBOXETINE TO TREAT NARCOLEPSY | June 2022 | February 2024 | Allow | 20 | 0 | 0 | Yes | No |
| 17843569 | CRYSTALLINE FORMS OF A BIPHENYL COMPOUND | June 2022 | September 2024 | Abandon | 27 | 1 | 1 | No | No |
| 17836602 | IMIDAZOPYRIDAZINE AND IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF | June 2022 | February 2024 | Allow | 20 | 0 | 0 | Yes | No |
| 17834626 | PREVENTION OF ROSACEA INFLAMMATION | June 2022 | December 2024 | Allow | 30 | 1 | 1 | Yes | No |
| 17750698 | METHODS OF TREATING ELEVATED PLASMA CHOLESTEROL | May 2022 | December 2023 | Allow | 19 | 0 | 1 | Yes | No |
| 17747084 | Chiral Indole Compounds and Their Use | May 2022 | July 2024 | Abandon | 26 | 1 | 1 | Yes | No |
| 17739757 | METHODS OF TREATING METABOLIC DISEASES WITH FUSED BICYCLIC PYRAZOLES | May 2022 | March 2025 | Allow | 34 | 2 | 1 | Yes | No |
| 17735217 | Bromocriptine Formulations | May 2022 | November 2023 | Allow | 18 | 0 | 0 | Yes | No |
| 17735918 | CONTRACEPTIVE COMPOUNDS AND METHODS | May 2022 | May 2023 | Allow | 12 | 0 | 0 | Yes | No |
| 17724537 | COMPOSITIONS COMPRISING AMINO ACIDS FOR USE IN THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION-RELATED DISEASES | April 2022 | December 2023 | Allow | 20 | 0 | 0 | Yes | No |
| 17720529 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | April 2022 | December 2024 | Abandon | 32 | 1 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CHANDRAKUMAR, NIZAL S.
With a 25.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 39.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner CHANDRAKUMAR, NIZAL S works in Art Unit 1625 and has examined 2,471 patent applications in our dataset. With an allowance rate of 73.6%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 22 months.
Examiner CHANDRAKUMAR, NIZAL S's allowance rate of 73.6% places them in the 30% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by CHANDRAKUMAR, NIZAL S receive 1.23 office actions before reaching final disposition. This places the examiner in the 22% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by CHANDRAKUMAR, NIZAL S is 22 months. This places the examiner in the 79% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.
Conducting an examiner interview provides a +24.8% benefit to allowance rate for applications examined by CHANDRAKUMAR, NIZAL S. This interview benefit is in the 75% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 36.1% of applications are subsequently allowed. This success rate is in the 77% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 62.4% of cases where such amendments are filed. This entry rate is in the 84% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 156.5% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 90% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 94.4% of appeals filed. This is in the 83% percentile among all examiners. Of these withdrawals, 72.1% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 58.3% are granted (fully or in part). This grant rate is in the 74% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 9.4% of allowed cases (in the 95% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 7.0% of allowed cases (in the 84% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.